Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2025-09-29
DOI
https://doi.org/10.1186/s13058-025-02108-4
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Jennifer R. Bellon, Filipa C. Lynce, R. Shi, Meredith M. Regan et al.
Breast Cancer Research
Breast Cancer Treatment Studies
article

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

Jennifer R. Bellon, Filipa C. Lynce, R. Shi, Meredith M. Regan, Faina Nakhlis, Beth Harrison, Molly K. DiLullo, Lei Qin, Laura Warren, McKenna Moore, Kristina A. Fanucci, Camden Bay, Ashka Patel, Sara M. Tolaney, Steven Van Laere, Zachary T. Herbert, Beth Overmoyer, Eren D. Yeh, Jennifer L. Guerriero
article en

Abstract

No abstract available for this paper.
Breast Cancer ResearchVol. 27(1)
Brigham and Women's Hospital (US), Harvard University (US), University of Antwerp (BE), Dana-Farber Cancer Institute (US), Takeda (United States) (US)
Eisai
Openalex Percentile: Top 67%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study — Jennifer R. Bellon, Filipa C. Lynce, et al. · Breast Cancer Research (2025) | TGRS Research Map | TGRS